Timothy Eugene Sullivan, Chief Financial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 6,000 shares at $63.95 ($379K) on 2024-03-01, disclosed to the SEC on 2024-03-05.
Scheduled sale ($379k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.86 | 4,000 | $251K | 66.3% |
| 2 | $63.95 | 2,000 | $128K | 33.7% |
| Total | $63.22 avg | 6,000 | $379K | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $86K | — | Filing → |
| APLS | SELL | 2025-10-23 | $280K | — | Filing → |
| APLS | SELL | 2025-09-10 | $2.1M | — | Filing → |